Rebif Rebidose (interferon beta-1a) NDC 44087-0188

NDC codes

FDA NDC Directory

Product NDC (as listed)44087-0188Labeler and product segments. Claims need a package NDC.

Product NDC at billing width44087-0188Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
44087-0188-1	44087018801	1 KIT in 1 CARTON (44087-0188-1) * .2 mL in 1 PACKAGE * .5 mL in 1 PACKAGEMarketed from Dec 21, 2012

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Rebif Rebidose
Generic name (nonproprietary): interferon beta-1a
Dosage form: Kit
Route: Subcutaneous
Labeler: EMD Serono, Inc.
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 103780
Marketing start: Dec 21, 2012
Listing expires: Dec 31, 2026
Identifiers: Product ID 44087-0188_037d2645-544b-41bb-bea8-00b578366ac6SPL ID 037d2645-544b-41bb-bea8-00b578366ac6SPL set ID c6fcb5d2-8fcd-44fa-a838-b84ee5f44f0fRxCUI 758025, 758027, 758028, 758029, 758030, 758032, 795748, 795749, 1649994, 1649996, 1650003, 1650004, 1650011, 1650012, 1650268, 1650282UNII XRO4566Q4R

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N444087018801 followed by a unit qualifier and the quantity

Package 44087-0188-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 22, 2025.

Indications (excerpt from the label)

REBIF is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Rebif is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 103780

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 103780
Product	Strength	Form · route	Labeler	Product NDC
Rebif Rebidoseinterferon beta-1a	Interferon beta-1a 22 ug/.5mL	Injection, SolutionSubcutaneous	EMD Serono, Inc.	44087-3322
Rebif Rebidoseinterferon beta-1a	Interferon beta-1a 44 ug/.5mL	Injection, SolutionSubcutaneous	EMD Serono, Inc.	44087-3344
Rebifinterferon beta-1a	—	KitSubcutaneous	EMD Serono, Inc.	44087-8822
Rebifinterferon beta-1a	Interferon beta-1a 44 ug/.5mL	Injection, SolutionSubcutaneous	EMD Serono, Inc.	44087-0044
Rebifinterferon beta-1a	Interferon beta-1a 22 ug/.5mL	Injection, SolutionSubcutaneous	EMD Serono, Inc.	44087-0022